Mounjar and Zepbound sales soar, Eli Lilly's Q3 results exceed expectations, and full-year guidance is raised.
```
Thanks to the continued strong market demand for the weight-loss drug Zepbound and the diabetes treatment Mounjaro, Eli Lilly's third-quarter results far exceeded market expectations and the company raised its full-year guidance.
Eli Lilly’s earnings report released on Thursday shows that third-quarter earnings per share were $7.